RIVVE Expands into Tunisia
Press Release - March 2026
RIVVE Life Science Expands into Tunisia, Advancing Its Regional Commercialization Platform
RIVVE Life Science, a GCC-focused pharmaceutical commercialization partner, today announced its expansion into Tunisia through a strategic partnership with MC Pharma. This development marks a significant step in RIVVE’s broader regional growth strategy, following its recent expansion across the Gulf Cooperation Council (GCC).
Building on its established presence in the UAE, Saudi Arabia, and wider GCC markets, RIVVE is extending its commercialization platform into North Africa, offering biopharmaceutical partners a more comprehensive and integrated regional footprint.
Through its partnership with MC Pharma, RIVVE will provide end-to-end commercialization support in Tunisia, including regulatory strategy, market access, pricing and reimbursement, and commercial execution. This expansion enables global biopharma companies to efficiently enter and scale within the Tunisian market while benefiting from RIVVE’s regional expertise and operational capabilities.
“Following our successful expansion across the GCC, our entry into Tunisia reflects a strong opportunity aligned with increasing demand from our global partners,” said Mostafa Nagib, Chief Executive Officer of RIVVE Life Science. “Our partnership with MC Pharma strengthens our ability to support biopharmaceutical companies with seamless market entry across both the GCC and North Africa, while maintaining the highest standards of compliance and execution.”
“Tunisia represents an important addition to our growing regional footprint, enabling us to further support our partners in accessing high-potential markets,” said Rana Osama, Business Development Executive at RIVVE Life Science. “Through our collaboration with MC Pharma, we are well-positioned to deliver localized expertise and accelerate product commercialization while addressing the evolving needs of patients and healthcare systems in North Africa.”
RIVVE Life Science operates within a broader regional ecosystem alongside established commercialization companies, including NewBridge Pharmaceuticals, Genpharma, GAIA Healthcare, and now MC Pharma. Through its differentiated and agile model, RIVVE continues to deliver tailored solutions that address the evolving needs of regional healthcare markets and enable partners to unlock new growth opportunities.
Become Our Partner
About RIVVE Life Science
RIVVE Life Science is a GCC-focused pharmaceutical commercialization partner, providing integrated, end-to-end services across regulatory strategy, market access, and commercial execution. The company’s mission is to enable biopharmaceutical organizations to successfully establish, expand, and sustain their presence across the UAE, Saudi Arabia, and the wider Middle East.